Lilly gets FDA EUA for bebtelovimab in mild-to-moderate Covid-19
Eli Lilly and Company (Lilly) has secured Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for bebtelovimab for the treatment of ... Read More
Lilly begins real-world Covid-19 study of bamlanivimab in New Mexico to assess outcomes in high-risk patients
Eli Lilly begins a real-world Covid-19 study of bamlanivimab in New Mexico. Find out how mobile clinics aim to reduce hospitalizations in high-risk patients. Read More
Lilly partners with UnitedHealth Group for pragmatic study of bamlanivimab in high-risk COVID-19 patients
Eli Lilly and Company (Lilly) has formed a strategic collaboration with UnitedHealth Group to conduct a pragmatic clinical study on bamlanivimab (LY-CoV555), a monoclonal antibody ... Read More
FDA grants emergency use authorization for Bamlanivimab to treat Covid-19
The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for bamlanivimab (LY-CoV555), a neutralizing antibody developed by Eli Lilly and Company ... Read More
Lilly secures $375m deal with US govt for bamlanivimab Covid-19 treatment
Eli Lilly and Company (Lilly), a global pharmaceutical leader, has signed a significant $375 million agreement with the US government for the supply of 300,000 ... Read More